[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myelopathy-cervical\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myelopathy-cervical":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,71,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100571370","evaluation-of-gait-impairment-and-correlation-in-patients-with-dcm-100571370",false,"NCT06719375","Evaluation of Gait Impairment and Correlation in Patients With DCM","Evaluation of Gait Impairment and Correlation With Clinical Assessment Tools Before and After Surgery in Patients With Cervical Myelopathy Using Inertial Sensors","DCM-HFIMU","Inclusion Criteria:\n\n* Age 18 years or older.\n* Able to communicate and provide informed consent.\n* Capable of walking at least 3 meters without assistance from others or walking aids.\n* No prior surgical treatment for cervical myelopathy.\n* Lower limb motor function score of 2 or higher on the mJOA scale.\n\nExclusion Criteria:\n\n* Presence of severe respiratory or cardiac conditions that impede safe walking.\n* Musculoskeletal issues, such as spinal deformities, affecting gait.\n* History of neurological disorders affecting gait, including peripheral nerve injury, joint stiffness, stroke, traumatic brain injury, myelitis, or Parkinson's disease.\n* Prior orthopedic or neurosurgical interventions that could impact gait.\n* Cervical conditions resulting from trauma (acute fracture or acute disc herniation), tumor, or infection.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","50 Days","OBSERVATIONAL","This study aims to evaluate gait impairment in patients with Degenerative Cervical Myelopathy (DCM) before and after surgery using an inertial measurement unit (IMU) sensor. By comparing IMU-derived gait parameters with traditional clinical assessment tools (e.g., Modified Ashworth Scale, mJOA, and GRASSP), the study seeks to determine the effectiveness and reliability of IMU sensors for assessing and monitoring gait improvement and neurological recovery in DCM patients. This study is conducted outside the United States and does not involve interventions or devices subject to U.S. FDA regulation.",[26],"Myelopathy Cervical","NOT_YET_RECRUITING","2025-06-20",{"date":30,"type":31},"2025-06-25","ACTUAL",{"date":33,"type":21},"2025-10-01",{"date":35,"type":21},"2025-12-31",{"name":37,"class":38},"Pusan National University Yangsan Hospital","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":17,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100513888","pilot-study-of-zetafuse-bone-graft-for-the-treatment-of-cervical-degenerative-disc-disease-100513888","NCT05971329","Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease","Inclusion Criteria:\n\n1. Age 22 to 75 years (inclusive) at the time of enrollment.\n2. Diagnosis of radiculopathy and\u002For myelopathy of the cervical spine, with pain, paresthesias or paralysis in a specific nerve root distribution C3 through C7, including at least one of the following:\n\n   * Neck and\u002For arm pain (at least 3 on the 0 - 10 numeric rating scale for pain.\n   * Decreased muscle strength of at least one level on the clinical evaluation 0 to 5 scale.\n   * Abnormal sensation including hyperesthesia or hypoesthesia. and\u002For\n   * Abnormal reflexes.\n3. Symptomatic at one or two contiguous levels from C3 to C7.\n4. Radiographically determined pathology at the level to be treated correlating to primary symptoms including at least one of the following:\n\n   * Decreased disc height on radiography, computed tomography (CT), or magnetic resonance imaging (MRI) in comparison to a normal adjacent disc.\n   * Degenerative spondylosis on CT or MRI.\n   * Disc herniation on CT or MRI.\n5. Neck Disability Index Score ≥ 30\u002F100.\n6. Unresponsive to non-operative treatment (e.g., rest, heat, physical therapy, chiropractor, massage, pain medication) for approximately six weeks from the symptom onset; or has the presence of progressive symptoms or signs of nerve root\u002Fspinal cord compression in the face of continued non-operative management.\n7. No previous surgical intervention at the involved levels or any subsequent, planned\u002Fstaged surgical procedure at the involved or adjacent levels.\n8. Appropriate for treatment using an anterior surgical approach.\n9. Skeletally mature at the time of the surgery.\n10. Medically cleared for surgery.\n11. If a female of child-bearing potential, subject is non-pregnant, nonnursing, and agrees not to become pregnant during the study period.\n12. Willing and able to comply with the study plan.\n13. Signed written Patient Informed Consent Form.\n14. Willing to discontinue use of non-steroidal anti-inflammatory drugs (NSAIDs) from one week before the surgery to 3 months after the surgery.\n\nExclusion Criteria:\n\n1. A cervical spinal condition other than symptomatic cervical degenerative disc disease requiring surgical treatment at the involved levels.\n2. Documented or diagnosed cervical instability relative to adjacent segments at either level, defined by dynamic (flexion\u002Fextension) radiographs showing sagittal plane translation \\>3.5 mm or sagittal plane angulation \\> 20°.\n3. More than two cervical levels requiring surgical treatment.\n4. An immobile or spontaneously fused level adjacent to the levels to be treated.\n5. Severe pathology of the facet joints of the involved vertebral bodies.\n6. Previous surgical intervention at either one or both of the involved levels or at adjacent levels.\n7. History of trauma to the C3 to C7 levels resulting in significant bony or disco-ligamentous cervical spine injury.\n8. Previously diagnosed with osteomalacia;\n9. Any of the following that may be associated with an increased risk osteoporosis (if \"Yes\" to any of the below risk factors, a DEXA Scan is required to determine eligibility). If the level of bone mineral density (BMD) on DEXA scan is a T score of -2.5 or worse (i.e., -2.6, - 2.7, etc.) the subject is ineligible for the study.\n\n   * Postmenopausal non-Black female over 60 years of age who weighs less than 140 pounds.\n   * Postmenopausal female who has sustained a non-traumatic hip, spine, or wrist fracture.\n   * Male over the age of 60 who has sustained a non-traumatic hip or spine fracture.\n   * Taking bisphosphonate medication for the treatment of osteoporosis.\n   * Chronic use of high dose steroids.\n10. Reported active malignancy that included a history of any invasive malignancy (except non-melanoma skin cancer) unless the subject had been treated with curative intent and there had been no clinical signs or symptoms of the malignancy for at least five years.\n11. Overt or active systemic infection, or infection at the operative site.\n12. Insulin dependent diabetes.\n13. A tobacco user who does not agree to suspend smoking prior to surgery.\n14. Chronic or acute renal failure or prior history of renal disease.\n15. Mentally incompetent (If questionable, obtain psychiatric consult).\n16. A prisoner.\n17. An alcohol and\u002For drug abuser currently or recently undergoing treatment for alcohol and\u002For drug abuse.\n18. Involved with current or pending litigation regarding a spinal condition.\n19. Received drugs that may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., steroids or methotrexate) excluding routine perioperative anti-inflammatory drugs.\n20. A history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers- Danlos Syndrome, or osteogenesis imperfecta).\n21. A condition that requires post-operative medications that interfere with the stability of the implant, such as steroids. (This does not include low dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs).\n22. Received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following implantation with the ZetaFuse™ Bone Graft device.",true,"22 Years","75 Years",{"count":49,"type":21},10,"INTERVENTIONAL",[52],"NA","The goal of this pilot clinical trial is to test the safety and preliminary performance of the ZetaFuse Bone Graft in patient requiring fusion of the C3-C7 vertebral bones due to pain or loss of neurological function.\n\nParticipants will be treated with ZetaFuse during surgical intervention to reduce pain and the loss of neurological function.",[55,26,56,57,58],"Radiculopathy, Cervical","Neurological Abnormality","Disc Disease","Disc Degeneration","RECRUITING","2025-04-18",{"date":62,"type":31},"2025-04-24",{"date":64,"type":21},"2026-09",{"date":66,"type":21},"2027-09",{"name":68,"class":69},"Zetagen Therapeutics, Inc","INDUSTRY",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":50,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100310391","enhancing-recovery-in-non-traumatic-spinal-cord-injury-100310391","NCT03320759","Enhancing Recovery in Non-Traumatic Spinal Cord Injury","Enhancing Recovery in Non-Traumatic Spinal Cord Injury: Implementation of an Integrated Program for the Assessment of Rehabilitation Therapies","Inclusion Criteria:\n\n* right-handed\n* have a history of progressive neurological deficits \\\u003C24 months\n* eligible for MRI scanning\n\nExclusion Criteria:\n\n* having any other neurological disorder or systemic disease that can impair neurological function\n* not fluent in reading and speaking English\n* being claustrophobic\n* unable to follow simple task instructions and maintain standardized movements\n* being unable to return for all follow-up imaging and rehabilitation sessions",{"count":79,"type":21},40,[52],"The investigators have spent the last decade uncovering unique metabolic and functional abnormalities in the brains of patients with spinal cord compression. Degenerative spinal cord compression represents a unique model of reversible spinal cord injury. In the investigator's previous work, they have demonstrated that cortical reorganization and recruitment is associated with metabolic changes in the brains of patients recovering from spinal cord compression and is correlated with recovery and improved neurological scores.\n\nThe goal of this study is to combine a rigorous platform of clinical care that includes preoperative evaluation, surgery, and rehabilitation, with state of the art imaging techniques to demonstrate how rehabilitative therapy can increase brain plasticity and recovery of neurological function in patients with spinal cord injury. Neurological function will be carefully evaluated in two groups of patients, those receiving rehabilitation and those not receiving rehabilitation after spine surgery, and will be correlated with the results of advanced imaging.",[83,84,85,26],"Spinal Cord Compression","Spinal Cord Injuries","Cervical Spondylosis","2024-03-26",{"date":88,"type":31},"2024-03-28",{"date":90,"type":31},"2018-08-21",{"date":92,"type":21},"2026-07-01",{"name":94,"class":38},"Western University, Canada",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":50,"phases":106,"briefSummary":107,"conditions":108,"keywords":125,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":95},"100410368","cervical-arthroplasty-cost-effectiveness-study-caces-100410368","NCT04623593","Cervical Arthroplasty Cost Effectiveness Study (CACES)","Economic Evaluation of Anterior Cervical Discectomy With Arthroplasty Versus Anterior Cervical Discectomy With Fusion in the Surgical Treatment of Cervical Degenerative Disc Disease, a Randomized Controlled Trial","CACES","Inclusion Criteria:\n\n* Indication for anterior cervical decompression surgery.\n* Single- or multilevel CDDD between C3 and C7.\n* Symptoms of myelopathy, radiculopathy, or myeloradiculopathy.\n* In case of pure radiculopathy: refractory to at least 6 weeks of conservative therapy.\n* In case of myelopathy: symptomatic myelopathy.\n* Patients ≥ 18 years of age.\n\nExclusion criteria\n\n* Indication for (additional) posterior surgical approach.\n* Indication for additional stabilization of the pathological segment by a plate.\n* Previous ventral surgery of the cervical spine.\n* Traumatic origin of the compression.\n* Previous radiotherapy of the cervical spine.\n* Metabolic bone disease.\n* Inflammatory spinal disease: e.g., Bechterew's disease, Forestier's disease.\n* Infection of the cervical spine.",{"count":105,"type":21},198,[52],"To date, no consensus exists on which anterior surgical technique is more cost-effective to treat cervical degenerative disc disease (CDDD). The most commonly used surgical treatment for patients with single- or multilevel symptomatic CDDD is anterior cervical discectomy with fusion (ACDF). However, new complaints of radiculopathy and\u002For myelopathy commonly develop at adjacent levels, also known as clinical adjacent segment pathology (CASP). It remains unknown to what extent kinematics, surgery-induced fusion and natural history of disease play a role in its development. Anterior cervical discectomy with arthroplasty (ACDA) is thought to reduce the incidence of CASP by preserving motion in the operated segment. ACDA is often discouraged as the implant costs are higher whilst the clinical outcomes are similar to ACDF. However, preventing CASP might be a reason for ACDA to be a more cost-effective technique in the long-term.\n\nIn this randomized controlled trial patients will be randomized to receive ACDF or ACDA in a 1:1 ratio. Adult patients with single- or multi-level CDDD and symptoms of radiculopathy and\u002For myelopathy will be included. The primary outcome is cost-effectiveness and cost-utility of both techniques from a societal perspective. Secondary objectives are the differences in clinical and radiological outcomes between the two techniques, as well as the qualitative process surrounding anterior decompression surgery. All outcomes will be measured at baseline and every 6 months till 4 years postoperatively.\n\nHigh quality evidence regarding the cost-effectiveness of both ACDA and ACDF is lacking, to date no prospective trials from a societal perspective exist. Considering the ageing of the population and the rising healthcare costs, the need for a solid clinical cost-effectiveness trial addressing this question is high.",[55,26,109,110,111,112,113,114,115,116,117,118,119,85,120,121,122,123,124],"Myelopathy, Compressive","Radiculopathy, Cervical Region","Radiculopathy; in Spondylosis","Radiculopathy; in Intervertebral Disc Disorder","Myelopathy Neurological","Myelopathy Due to Spondylosis","Cervical Disc Disease","Cervical Disc Herniation","Cervical Disc Degeneration","Cervical Disc Disorder With Myelopathy","Cervical Disc Prolapse With Myelopathy","Cervical Fusion","Cervical Disc Disorder With Radiculopathy","Cervical Disc Prolapse With Radiculopathy","Fusion of Spine","Disc Prolapse Cervical",[126,127,128,129,130,131,132,133,134,135,136,137,138,139],"Cost-effectivity","Economic evaluation","Health Utility","Randomised controlled trial","RCT","ACDA","ACDF","Anterior cervical discectomy and fusion","Anterior cervical discectomy with arthroplasty","Degenerative cervical myelopathy","Degenerative cervical radiculopathy","ASD","Adjacent Segment Disease","Adjacent Level Disease","2024-01-24",{"date":142,"type":31},"2024-01-25",{"date":144,"type":31},"2022-01-17",{"date":146,"type":21},"2028-06-01",{"name":148,"class":38},"Valérie Schuermans"]